Ezetimibe improves glucose metabolism by ameliorating hepatic function in Japanese patients with type 2 diabetes

Journal of Diabetes Investigation

Volumn 3, Issue 2, 2012, Pages 179-184

  Ichimori, Shinji ^a,b   Shimoda, Seiya ^a   Goto, Rieko ^a   Matsuo, Yasuto ^c   Maeda, Takako ^a   Furukawa, Noboru ^a   Kawashima, Junji ^a   Kodama, Shoko ^d   Sekigami, Taiji ^e   Isami, Satoshi ^b   Nishida, Kenro ^f   Araki, Eiichi ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b Ueki Hospital   (Japan)

^c SAISEIKAI KUMAMOTO HOSPITAL   (Japan)

^d NATIONAL HOSPITAL ORGANIZATION KUMAMOTO MEDICAL CENTER   (Japan)

^e Yatsushiro Social Insurance General Hospital   (Japan)

^f Minamata City Hospital and Medical Center   (Japan)

Author keywords

Ezetimibe; Hepatic insulin sensitivity; Liver steatosis

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; EZETIMIBE; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG RESPONSE; FEMALE; GLUCOSE METABOLISM; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERCHOLESTEROLEMIA; JAPANESE; LIVER DYSFUNCTION; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; TREATMENT DURATION;

EID: 84859137880     PISSN: 20401116     EISSN: 20401124     Source Type: Journal    
DOI: 10.1111/j.2040-1124.2011.00147.x     Document Type: Article

References (22)

1. Sone H, Tanaka S, Iimuro S, et al. Long-term lifestyle intervention lowers the incidence of stroke in Japanese patients with type 2 diabetes: a nationwide multicentre randomised controlled trial (the Japan Diabetes Complications Study). Diabetologia 2010; 53: 419-428.
2. Strandberg TE, Tilvis RS, Pitkala KH, et al. Cholesterol and glucose metabolism and recurrent cardiovascular events among the elderly: a prospective study. J Am Coll Cardiol 2006; 48: 708-714.
3. Lally S, Tan CY, Owens D, et al. mRNA levels of genes involved in dysregulation of postprandial lipoproteins in type 2 diabetes: the role of Niemann Pick C1-like 1, ABCG5 and G8 and microsomal triglyceride transfer protein. Diabetologia 2006; 49: 1008-1016.
4. Davies JP, Scott C, Oishi K, et al. Inactivation of NPC1L1 causes multiple lipid transport defects and protects against diet-induced hypercholesterolemia. J Biol Chem 2005; 280: 12710-12720.
5. Deushi M, Nomura M, Kawakami A, et al. Ezetimibe improves liver steatosis and insulin resistance in obese rat model of metabolic syndrome. FEBS Lett 2007; 581: 5664-5670.
6. Muraoka T, Aoki K, Iwasaki T, et al. Ezetimibe decreases SREBP-1c expression in liver and reverses hepatic insulin resistance in mice fed a high-fat diet. Metabolism 2010; 60: 617-628.
7. Nozaki Y, Fujita K, Yoneda M, et al. Long-term combination therapy of ezetimibe and acarbose for non-alcoholic fatty liver disease. J Hepatol 2009; 51: 548-556.
8. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 2003; 37: 1202-1219.
9. American Gastroenterological Association. American Gastroenterological Association medical position statement: nonalcoholic fatty liver disease. Gastroenterology 2002; 123: 1702-1704.
10. Seino Y, Nanjo K, Tajima N, et al. Report of the Committee on the Classification and Diagnostic Criteria of Diabetes Mellitus. The Committee of the Japan Diabetes Society on the Diagnostic Criteria of Diabetes Mellitus. Diabetol Int 2010; 1: 2-20.
11. Kojima S, Watanabe N, Numata M, et al. Increase in the prevalence of fatty liver in Japan over the past 12years: analysis of clinical background. J Gastroenterol 2003; 38: 954-961.
12. Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis. Med Clin North Am 1996; 80: 1147-1166.
13. Pinto HC, Baptista A, Camilo ME, et al. Nonalcoholic steatohepatitis. Clinicopathological comparison with alcoholic hepatitis in ambulatory and hospitalized patients. Dig Dis Sci 1996; 41: 172-179.
14. Sorbi D, Boynton J, Lindor KD. The ratio of aspartate aminotransferase to alanine aminotransferase: potential value in differentiating nonalcoholic steatohepatitis from alcoholic liver disease. Am J Gastroenterol 1999; 94: 1018-1022.
15. Wallerstedt S, Olsson R, Waldenström J. The diagnostic significance of a high ASAT-ALAT (GOT-GPT) ratio in patients with very high serum aminotransferase levels. Acta Med Scand 1974; 195: 227-229.
16. Bajaj M, Suraamornkul S, Kashyap S, et al. Sustained reduction in plasma free fatty acid concentration improves insulin action without altering plasma adipocytokine levels in subjects with strong family history of type 2 diabetes. J Clin Endocrinol Metab 2004; 89: 4649-4655.
17. Santomauro AT, Boden G, Silva ME, et al. Overnight lowering of free fatty acids with Acipimox improves insulin resistance and glucose tolerance in obese diabetic and nondiabetic subjects. Diabetes 1999; 48: 1836-1841.
18. Güçlü F, Ozmen B, Hekimsoy Z, et al. Effects of a statin group drug, pravastatin, on the insulin resistance in patients with metabolic syndrome. Biomed Pharmacother 2004; 58: 614-618.
19. Yamada T, Fukatsu M, Suzuki S, et al. Fatty liver predicts impaired fasting glucose and type 2 diabetes mellitus in Japanese undergoing a health checkup. J Gastroenterol Hepatol 2010; 25: 352-356.
20. Lonardo A, Lombardini S, Scaglioni F, et al. Fatty liver, carotid disease and gallstones: a study of age-related. World J Gastroenterol 2006; 12: 5826-5833.
21. Tenenbaum T, Fisman EZ, Boyko V, et al. Attenuation of progression of insulin resistance in patients with coronary artery disease by bezafibrate. Arch Intern Med 2006; 166: 737-741.
22. 2+-superoxide dismutase in the liver. Life Sci 1998; 63: 135-144.